Loading...
Nous aimerions que vous fassiez partie de notre communauté. Rejoignez notre Discord pour échanger avec nous et les autres membres !
- Ticker
- MVIR.ST
- Price
- 0.55
- Stock movement down
- -0.10 (-5.03%)
- Company name
- Medivir AB
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Capitalisation boursière
- 207.74M
- Valeur d'entreprise
- -
- Cours/chiffre d'affaires
- -
- Cours/valeur comptable
- -
- Rendement du div
- -
- Croissance du div
- -
- Années de croissance
- -
- Versement FCF
- -
- Trailing P/E
- -
- P/E prévisionnel
- -
- PEG
- -
- Croissance EPS
- -
- Rendement sur 1 an
- -38.68%
- Rendement sur 3 ans
- -38.00%
- Rendement sur 5 ans
- -31.30%
- Rendement sur 10 ans
- -30.66%
Dernière modification : 2025-09-17
DIVIDENDES
MVIR.ST ne verse pas de dividendes
VALORISATION
Ratios de valorisation
Loading...
Données de ratios de valorisation
| Trailing P/E | - |
| Cours/OCF | - |
| Cours/FCF | - |
| Cours/EBITDA | - |
| EV/EBITDA | - |
Valorisation (Chiffre d'affaires/valeur comptable)
Loading...
Données de valorisation (Chiffre d'affaires/valeur comptable)
| Cours/chiffre d'affaires | - |
| Cours/valeur comptable | - |
| EV/chiffre d'affaires | - |
DONNEES FINANCIERES
INFORMATIONS SUR LES ACTIONS
Graphique boursier
Loading...
Données du prix des actions
| Ouverture | 1.97 |
| Max journalier | 2.00 |
| Min journalier | 1.85 |
| Volume journalier | 182K |
| Niveau record | 190.06 |
| Estimation des analystes sur 1 an | 18.71 |
| Beta | -0.30 |
| EPS (TTM) | - |
| Dividende par action | 0.00 |
| Date ex-div | - |
| Prochaine date de bénéfices | 6 Nov 2025 |
Potentiel de baisse
Loading...
Données du potentiel de baisse
| MVIR.ST | S&P500 | |
| Baisse de prix actuelle par rapport au niveau record | -99.71% | -0.20% |
| Baisse de prix actuelle la plus importante | -99.35% | -19.00% |
| Date de la baisse la plus importante | 7 Apr 2025 | 8 Apr 2025 |
| Baisse moyenne par rapport au record | -75.66% | -2.76% |
| Délai moyen pour nouveau record | 407 days | 5 days |
| Délai max pour nouveau record | 6471 days | 89 days |
INFORMATIONS SUR LA SOCIETE
Capitalisation boursière
207.74M
Catégorie de capitalisation boursière
Small-cap
Description
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat HDAC inhibitor for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma. In addition, the company is developing MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors, as well as USP-1/TNG348, USP-7, and MBLI/MET-X, which completed preclinical trials for treating cancer and infection. It has a collaboration and supply agreement with Eisai to evaluate fostrox, a liver-targeted treatment, in combination with lenvatinib for the treatment of liver cancer. The company was incorporated in 1987 and is based in Huddinge, Sweden.
Employés
10
Site internet
Communication financière
-
Dossiers SEC
CEO
Pays
Sweden
Ville
Type d'action
-
Statut CCC
-
Fréquences des dividendes
-
EVENEMENTS ET PRESENTATIONS
EvénementsPrésentations
Loading...
COMPRENDRE LE METIER
Loading...
ACTUALITES DE LA SOCIETE
Toute l'actualitéCommuniqués de presse
Medivir AB (STU:MVR0) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Medivir AB (STU:MVR0) reports promising clinical developments and patent extensions, while navigating funding hurdles to sustain its innovative pipeline.
22 août 2025
STOCKHOLM, SE / ACCESS Newswire / August 20, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusin...
20 août 2025
The European market has shown mixed performance recently, with the pan-European STOXX Europe 600 Index remaining flat over a four-day period, while major indexes such as France's CAC 40 and Italy's FT...
9 juillet 2025
As European markets continue to navigate a landscape marked by mixed performances and hopes for easing trade tensions, investors are increasingly seeking opportunities in less conventional areas. Penn...
15 mai 2025
Amid escalating trade tensions and the lowest consumer sentiment in nearly three years, European markets have experienced notable volatility. Despite these challenges, the concept of penny stocks rema...
16 avril 2025
As European markets navigate the complexities of U.S. trade tariffs and monetary policy uncertainties, the pan-European STOXX Europe 600 Index recently saw a slight decline. Despite these challenges, ...
18 mars 2025
Medivir AB (FRA:MVR0) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Medivir AB (FRA:MVR0) reports significant progress in liver cancer treatment development, despite facing increased clinical costs and market competition.
19 février 2025
Global markets have recently experienced mixed performances, with major stock indexes showing a combination of gains and declines as the year closed out. For investors looking beyond traditional blue-...
6 janvier 2025